Pharsight

Lutathera patents expiration

LUTATHERA Litigations
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10596276 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(14 years from now)

US10596278 AAA USA INC Stable, concentrated radionuclide complex solutions
Jul, 2038

(14 years from now)

Lutathera is owned by Aaa Usa Inc.

Lutathera contains Lutetium Dotatate Lu-177.

Lutathera has a total of 2 drug patents out of which 0 drug patents have expired.

Lutathera was authorised for market use on 26 January, 2018.

Lutathera is available in solution;intravenous dosage forms.

Drug patent challenges can be filed against Lutathera from 2022-01-26.

The generics of Lutathera are possible to be released after 25 July, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Jan 26, 2023
Orphan Drug Exclusivity (ODE) Jan 26, 2025

Drugs and Companies using LUTETIUM DOTATATE LU-177 ingredient

NCE-1 date: 2022-01-26

Market Authorisation Date: 26 January, 2018

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

LUTATHERA family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic